Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of CKD-348(5) vs Co-administration of CKD-828, D097, D337
NCT05749861Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2023
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-348 in hypertension (HTN) and dyslipidemia (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-time Curve from time zero to the last measurable concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Started Apr 2023; status: completed.
02
Drugs
CKD-348
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT05749861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05749861.